Major pharmaceutical corporation Pfizer Inc. (PFE) recently channeled $25 million into acquiring a minority interest in Caribou Biosciences, Inc. (CRBU). This move aligns with previous strategies PFE has pursued over recent years, utilizing the substantial cash flow it generated from its COVID-19 product sales.
Despite this strong position, Credit Suisse analyst Trung Huynh downgraded the stock to a 'Hold' rating due to what he predicts as upcoming uncertainties and “limited pipeline catalysts.” Notwithstanding, he also recognized the attractiveness of the stock's valuation.
